Sequential biologic treatments for psoriasis
Official title: SEquential Treatment of PSoriasis With Biologics
Run by Royal United Hospitals Bath NHS Foundation Trust · NCT07187817 · Data updated 2026-11-12
This project uses past clinic records to see if people with psoriasis keep responding when they switch to three or more different biologic medicines.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 366 (estimated) |
| Sponsor | Royal United Hospitals Bath NHS Foundation Trust Academic / other |
| Locations | 1 site (Bath, Somerset) |
| Status | Recruiting |
| Started | October 14, 2025 |
| Main results expected | August 7, 2026 |
| Study ends | August 7, 2026 |
| Registry record updated | July 9, 2026 |
| Trial ID | NCT07187817 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people in the United Kingdom with dermatologist-diagnosed chronic plaque psoriasis who have previously received one to ten lines of biologic or targeted synthetic therapy.
✕Probably not a fit
People with non-plaque forms of psoriasis, patients treated outside the UK, or those without prior biologic treatment are unlikely to be represented or benefit from the study's conclusions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This retrospective observational cohort will collect anonymous routine clinic data from NHS dermatology centers across the United Kingdom. Sites will submit demographic information and treatment histories for patients with chronic plaque psoriasis who received one to ten lines of biologic or targeted synthetic therapies. For each line of therapy investigators will record baseline Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores and the scores at three and six months to measure response. Analysis will compare response rates across sequential biologic lines to see whether 3-month responses decline after the second biologic.
Why it matters
Potential benefit: If successful, the results could help clinicians predict how well patients are likely to respond to later-line biologic treatments and guide treatment choices.
How similar studies have gone: While many trials have shown strong responses to first- and second-line biologics, few studies have examined outcomes after three or more sequential biologics, so this question remains relatively untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of chronic plaque psoriasis by a Dermatology consultant * Prior treatment with biologic or targeted synthetic treatment (1 to 10 lines) for psoriasis in the United Kingdom Exclusion Criteria: * Diagnosis of other forms of psoriasis for example generalised pustular psoriasis
Where it's running
-
Royal United Hospitals Bath NHS Foundation Trust
Bath, Somerset, United Kingdom Recruiting
Study contacts
- Study coordinator: Charlotte Gollins
- Email: charlotteelizabeth.gollins@nhs.net
- Phone: 01225 826192
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HB0017 Injection safety and PK in low-weight adults at different injection sites
This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.
-
MK-8644: first-in-human test in healthy people and people with psoriasis
This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care
This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
SHR-1139 injectable treatment for adults with plaque psoriasis
This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.